San Francisco, CA

IPO July 2019 (NASDAQ: MIRM)

Mirum was formed, with support from RiverVest, to develop the compound previously developed by Lumena (see Lumena discussion above).  After Takeda’s acquisition of Shire, the compound, now called “Maralixibat”, became available. Maralixibat is a treatment for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), two life-threatening pediatric liver diseases. If left untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching.


© Copyright RiverVest® All Rights Reserved.